These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 830417)
41. Heterogeneity of keratin expression in mouse mammary hyperplastic alveolar nodules and adenocarcinomas. Asch HL; Asch BB Cancer Res; 1985 Jun; 45(6):2760-8. PubMed ID: 2580627 [TBL] [Abstract][Full Text] [Related]
42. Differences in progression of BALB/cfRIII and BALB/cfC3H mammary hyperplastic alveolar nodules transplanted into the gland-free fat pads of BALB/c mice. Basolo F; Fontanini G; Squartini F Cancer Res; 1988 Jun; 48(11):3197-202. PubMed ID: 2835155 [TBL] [Abstract][Full Text] [Related]
43. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy. Adler A; Altbaum I J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275 [TBL] [Abstract][Full Text] [Related]
44. Susceptibility of mammary-tumor-virus-free BALB-c mouse mammary nodule outgrowth cells in DNA synthesis to 3-methylcholanthrene tumorigenesis. Adamson R; Banerjee MR; Medina D J Natl Cancer Inst; 1971 Apr; 46(4):899-907. PubMed ID: 5573774 [No Abstract] [Full Text] [Related]
45. c-H-ras-1 expression in 7,12-dimethyl benzanthracene-induced Balb/c mouse mammary hyperplasias and their tumors. Cardiff RD; Gumerlock PH; Soong MM; Dandekar S; Barry PA; Young LJ; Meyers FJ Oncogene; 1988 Aug; 3(2):205-13. PubMed ID: 2842717 [TBL] [Abstract][Full Text] [Related]
46. X-ray microanalysis of electrolyte content of normal, preneoplastic, and neoplastic mouse mammary tissue. Smith NK; Stabler SB; Cameron IL; Medina D Cancer Res; 1981 Oct; 41(10):3877-80. PubMed ID: 7284996 [TBL] [Abstract][Full Text] [Related]
47. DNA repair in normal and preneoplastic mammary tissues. Bodell WJ; Banerjee MR Cancer Res; 1978 Mar; 38(3):736-40. PubMed ID: 626977 [TBL] [Abstract][Full Text] [Related]
48. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor. Gorelik L; Rubin M; Prokhorova A; Mokyr MB J Immunol; 1995 Apr; 154(8):3941-51. PubMed ID: 7706732 [TBL] [Abstract][Full Text] [Related]
49. Prophylaxis of early preneoplastic lesions of the mammary gland. Welsch CW Cancer Res; 1976 Jul; 36(7 PT 2):2621-5. PubMed ID: 1277169 [TBL] [Abstract][Full Text] [Related]
50. Survey of int region DNA rearrangements in C3H and BALB/cfC3H mouse mammary tumor system. Pathak VK; Strange R; Young LJ; Morris DW; Cardiff RD J Natl Cancer Inst; 1987 Feb; 78(2):327-31. PubMed ID: 3468297 [TBL] [Abstract][Full Text] [Related]
51. Elimination of V beta 2 bearing T-cells in BALB/c mice implanted with syngeneic preneoplastic and neoplastic mammary lesions. Wei WZ; Ficsor-Jacobs R; Tsai SJ; Pauley R Cancer Res; 1991 Jun; 51(12):3331-3. PubMed ID: 2040009 [TBL] [Abstract][Full Text] [Related]
52. p53 mutations selected in vivo when mouse mammary epithelial cells form hyperplastic outgrowths are not necessary for establishment of mammary cell lines in vitro. Ozbun MA; Jerry DJ; Kittrell FS; Medina D; Butel JS Cancer Res; 1993 Apr; 53(7):1646-52. PubMed ID: 8453637 [TBL] [Abstract][Full Text] [Related]
53. Preneoplastic transformation in mouse mammary tissue: identification and validation of intermediate biomarkers for chemoprevention. Telang NT; Kurihara H; Wong GY; Bradlow HL; Osborne MP Anticancer Res; 1991; 11(3):1021-7. PubMed ID: 1909512 [TBL] [Abstract][Full Text] [Related]
54. Suppression by kampo medicines in preneoplastic mammary hyperplastic alveolar nodules of SHN virgin mice. Sakamoto S; Muroi N; Matsuda M; Tajima M; Kudo H; Kasahara N; Suzuki S; Sugiura Y; Kuwa K; Namiki H Planta Med; 1993 Oct; 59(5):425-7. PubMed ID: 8255936 [TBL] [Abstract][Full Text] [Related]
55. Alterations of acquired mouse mammary tumor virus DNA during mammary tumorigenesis in BALB/cfC3H mice. Cardiff RD; Morris DW; Young LJ J Natl Cancer Inst; 1983 Nov; 71(5):1011-9. PubMed ID: 6316008 [TBL] [Abstract][Full Text] [Related]
56. Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. Tekmal RR; Ramachandra N; Gubba S; Durgam VR; Mantione J; Toda K; Shizuta Y; Dillehay DL Cancer Res; 1996 Jul; 56(14):3180-5. PubMed ID: 8764102 [TBL] [Abstract][Full Text] [Related]
57. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor. Mokyr MB; Kalinichenko TV; Gorelik L; Bluestone JA J Immunol; 1998 Feb; 160(4):1866-74. PubMed ID: 9469448 [TBL] [Abstract][Full Text] [Related]
58. Induction of mammary tumors in virgin female BALB/c mice by single low doses of 7,12-dimethylbenz[a]anthracene. Ethier SP; Ullrich RL J Natl Cancer Inst; 1982 Nov; 69(5):1199-203. PubMed ID: 6813553 [TBL] [Abstract][Full Text] [Related]
59. Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor. Mokyr MB; Barker E; Weiskirch LM; Takesue BY; Pyle JM Cancer Res; 1989 Aug; 49(16):4597-606. PubMed ID: 2568174 [TBL] [Abstract][Full Text] [Related]
60. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor. Bartik MM; Takesue BY; Mokyr MB Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]